Phase III study of efficacy and safety in Polycythemia Vera subjects who are restistant or intolerant of hydroxyurea

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-020807-57

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the efficacy of INC424 to Best Available Therapy (BAT) as assessed by both the absence of phlebotomy eligibility and reduction in spleen volume.


Critère d'inclusion

  • Polycythemia Vera